PMID- 25634182
OWN - NLM
STAT- MEDLINE
DCOM- 20150408
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 94
IP  - 4
DP  - 2015 Jan
TI  - Serum apelin level predicts the major adverse cardiac events in patients with ST 
      elevation myocardial infarction receiving percutaneous coronary intervention.
PG  - e449
LID - 10.1097/MD.0000000000000449 [doi]
LID - e449
AB  - The cardiovascular profile of the apelin makes it a promising therapeutic target 
      for heart failure and ischemic heart disease. However, it remains unknown whether 
      apelin affect the clinical outcome of patients with ST elevation myocardial 
      infarction (STEMI) and received percutaneous coronary intervention (PCI). We 
      enrolled a total of 120 patients with acute STEMI who underwent primary PCI. 
      Serum apelin was detected. After PCI procedure, all patients were followed for 12 
      months. The follow-up end-point was occurrence of major adverse cardiovascular 
      event (MACE). Lower serum apelin levels (<0.54 ng/mL) was significantly 
      associated with higher serum low density lipoprotein-cholesterol level, higher 
      peak creatine kinase MB fraction (CK-MB) and peak troponin-I (TNI) levels, the 
      number of obstructed vessels, and need for inotropic support. The incidence of 
      MACE was significantly higher in the low apelin group (23 patients out of 67) 
      than in the high apelin group (10 patients out of 75, P < 0.001). Kaplan-Meier 
      analysis revealed that the MACE-free rate was significantly lower in the patients 
      with low apelin than those with high apelin (P < 0.001, log rank test). The 
      multivariate Cox proportional hazard analysis adjusted with the clinical and 
      angiographic characteristic reveals that the serum low apelin is a predictor for 
      MACE incidence (hazard ratio = 2.36, 95% confidence interval: 1.83-3.87, 
      P = 0.004). The finding of this study suggests that the serum apelin may be used 
      as a marker to predict the MACE after PCI in patients with STEMI.
FAU - Liu, Hai-Tao
AU  - Liu HT
AD  - From the Department of Cardiology, Xijing Hospital, Fourth Military Medical 
      University, Xi'an, China.
FAU - Chen, Mai
AU  - Chen M
FAU - Yu, Jin
AU  - Yu J
FAU - Li, Wei-Jie
AU  - Li WJ
FAU - Tao, Ling
AU  - Tao L
FAU - Li, Yan
AU  - Li Y
FAU - Guo, Wen-Yi
AU  - Guo WY
FAU - Wang, Hai-Chang
AU  - Wang HC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (APLN protein, human)
RN  - 0 (Apelin)
RN  - 0 (Biomarkers)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Troponin I)
RN  - EC 2.7.3.2 (Creatine Kinase, MB Form)
SB  - IM
MH  - Apelin
MH  - Biomarkers/blood
MH  - Cardiotonic Agents/therapeutic use
MH  - China/epidemiology
MH  - Cholesterol, LDL/blood
MH  - Coronary Angiography
MH  - Coronary Occlusion/diagnostic imaging
MH  - Creatine Kinase, MB Form/blood
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/*blood
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myocardial Infarction/*blood/epidemiology/therapy
MH  - *Percutaneous Coronary Intervention
MH  - Recurrence
MH  - Stroke/blood/epidemiology
MH  - Troponin I/blood
PMC - PMC4602953
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2015/01/31 06:00
MHDA- 2015/04/09 06:00
PMCR- 2015/01/30
CRDT- 2015/01/31 06:00
PHST- 2015/01/31 06:00 [entrez]
PHST- 2015/01/31 06:00 [pubmed]
PHST- 2015/04/09 06:00 [medline]
PHST- 2015/01/30 00:00 [pmc-release]
AID - 00005792-201501040-00021 [pii]
AID - 10.1097/MD.0000000000000449 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2015 Jan;94(4):e449. doi: 10.1097/MD.0000000000000449.